Insights

Insights provides context and perspective about key pharmacy trends and issues

Care Management
The Everyday Epidemic
In the United States, and around the world, diabetes is a top spend, and trend, driver. Managing the condition is a complex issue for payors and for anyone with the diagnosis. Treatment... More
Feature
Expensive Pill Icon
Cost Management
Paying for Drugs Based on Outcomes
Value-based management seeks go beyond a static, pre-set price tag to uncover true value for drugs and better health for patients. More
Briefing
Drug Pipeline
Specialty Pharmacy Pipeline Drugs to Watch – Q3-Q4 2017
Key drugs to watch for in the specialty pharmacy pipeline Q3-Q4 2017 More
Specialty Report
Specialty
Potential Market Expansion for Prostate Cancer Drug
Blockbuster cancer drug Zytiga may become first-line treatment for patients with metastatic, castration-resistant cancer, greatly expanding its market and cost impact. More
Feature
Pharmacy Innovation
Evaluating Adherence in Accountable Care Organizations
New research in JAMA Cardiology shows that simply putting patients in an ACO does not improve adherence. Utilizing proven PBM interventions may help. More
Commentary
Expensive Pill
Cost Management
Aligning Drug Prices with Value
The current model of static, manufacturer-set drug prices is simply unsustainable. Value-based management approaches attempt to incentivize quality and efficacy. More
Briefing
Government Programs and Services
How Pharmacy Care Improves Health Outcomes
Despite lack of consistent national standards, payors can earn meaningful incentives for improvements to Medicaid quality measures. More
Briefing
Cost Management
New Guidelines for PCSK9 Inhibitors
New utilization management criteria ensure appropriate use of PCSK9 inhibitors, which can help lower bad cholesterol levels, but are significantly more expensive first-line therapies More
Briefing
Government Programs and Services
Medicaid Reform
Despite the lack of consistent, national quality measures, plans can achieve meaningful financial rewards by through improvements in pharmacy care. More
Briefing
Public Policy
A New Agenda for the FDA
A focus on prioritizing generic review and fostering competition could help in the battle against sky-rocketing prescription drug costs. More
Commentary